Advertisement

Neurological Sciences

, Volume 36, Issue 2, pp 203–208 | Cite as

Increased interictal serum levels of CXCL8/IL-8 and CCL3/MIP-1α in migraine

  • Halina Duarte
  • Antonio L. Teixeira
  • Natália P. Rocha
  • Renan B. DominguesEmail author
Original Article

Abstract

Inflammatory mediators have been studied in migraine pathophysiology; however, their role is not yet well established. The aim of the present study was to investigate interictal chemokine levels and its association with clinical parameters and psychiatric comorbidities in migraine patients compared with controls. This was a cross-sectional study including age and gender matched migraine patients and controls. Beck Depression and Anxiety Inventories, Headache Impact Test, and Allodynia Symptom Checklist were recorded. Chemokines were measured by ELISA. Forty-nine migraine patients and forty-nine controls without headache were included. CXCL8/IL-8 and CCL3/MIP-1α levels were significantly higher among patients with migraine (P = 0.039 and 0.02, respectively) even after controlling for anxiety and depression scores. Chemokine levels were not correlated with migraine impact as well as allodynia scores. CXCL8/IL-8 and CCL3/MIP-1 α levels were raised in migraine, independently of psychiatric comorbidities, migraine impact, and allodynia.

Keywords

Migraine Chemokines Anxiety Depression Allodynia 

Notes

Acknowledgments

This study was funded by CNPq and Fapemig, Brazil. We gratefully acknowledge the contribution of Cássio B. Lacerda and Tarnara Campostrini in data collection (School of Health Sciences of “Santa Casa de Misericordia de Vitoria”, Brazil).

Conflict of interest

None.

References

  1. 1.
    Noseda R, Burstein R (2013) Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain 154(Suppl):1Google Scholar
  2. 2.
    Perini F, D’Andrea G, Galloni E, Pignatelli F, Billo G et al (2005) Plasma cytokine levels in migraineurs and controls. Headache 45:926–931CrossRefPubMedGoogle Scholar
  3. 3.
    Sarchielli P, Alberti A, Baldi A, Coppola F, Rossi C et al (2006) Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 46:200–207CrossRefPubMedGoogle Scholar
  4. 4.
    Uzar E, Evliyaoglu O, Yucel Y, Ugur Cevik M, Acar A et al (2011) Serum cytokine and pro-brain natriuretic peptide (BNP) levels in patients with migraine. Eur Rev Med Pharmacol Sci 15:1111–1116PubMedGoogle Scholar
  5. 5.
    Bockowski L, Sobaniec W, Zelazowska-Rutkowska B (2009) Proinflammatory plasma cytokines in children with migraine. Pediatr Neurol 41:17–21CrossRefPubMedGoogle Scholar
  6. 6.
    Fidan I, Yuksel S, Ymir T, Irkec C, Aksakal FN (2006) The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol 171:184–188CrossRefPubMedGoogle Scholar
  7. 7.
    Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610–621CrossRefPubMedGoogle Scholar
  8. 8.
    Moreira MA, Tilbery CP, Monteiro LP, Teixeira MM, Teixeira AL (2006) Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand 114:109–113CrossRefPubMedGoogle Scholar
  9. 9.
    Teixeira AL Jr, Cardoso F, Souza AL, Teixeira MM (2004) Increased serum concentrations of monokine induced by interferon-gamma/CXCL9 and interferon-gamma-inducible protein 10/CXCL-10 in Sydenham’s chorea patients. J Neuroimmunol 150:157–162CrossRefPubMedGoogle Scholar
  10. 10.
    Gao YJ, Ji RR (2010) Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 126:56–68PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Sarchielli P, Alberti A, Vaianella L, Pierguidi L, Floridi A et al (2004) Chemokine levels in the jugular venous blood of migraine without aura patients during attacks. Headache 44:961–968CrossRefPubMedGoogle Scholar
  12. 12.
    Bo SH, Davidsen EM, Gulbrandsen P, Dietrichs E, Bovim G et al (2009) Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache. Cephalalgia 29:365–372CrossRefPubMedGoogle Scholar
  13. 13.
    Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders: 2nd edition. Cephalalgia 24(Suppl 1):S24–S101Google Scholar
  14. 14.
    Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893–897CrossRefPubMedGoogle Scholar
  15. 15.
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571CrossRefPubMedGoogle Scholar
  16. 16.
    Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963–974CrossRefPubMedGoogle Scholar
  17. 17.
    Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S et al (2008) Cutaneous allodynia in the migraine population. Ann Neurol 63:148–158PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Fontenelle LF, Barbosa IG, Luna JV, de Sousa LP, Abreu MN et al (2012) A cytokine study of adult patients with obsessive–compulsive disorder. Compr Psychiatry 53:797–804CrossRefPubMedGoogle Scholar
  19. 19.
    Teixeira AL, Reis HJ, Nicolato R, Brito-Melo G, Correa H et al (2008) Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:710–714CrossRefPubMedGoogle Scholar
  20. 20.
    Raddant AC, Russo AF (2011) Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med 13:e36PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Welch KM (1987) Migraine: a biobehavioral disorder. Arch Neurol 44:323–327CrossRefPubMedGoogle Scholar
  22. 22.
    Pietrobon D, Striessnig J (2003) Neurobiology of migraine. Nat Rev Neurosci 4:386–398CrossRefPubMedGoogle Scholar
  23. 23.
    Semple BD, Kossmann T, Morganti-Kossmann MC (2010) Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab 30:459–473PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Maurer M, von Stebut E (2004) Macrophage inflammatory protein-1. Int J Biochem Cell Biol 36:1882–1886CrossRefPubMedGoogle Scholar
  25. 25.
    Barbosa IG, Rocha NP, Bauer ME, de Miranda AS, Huguet RB et al (2013) Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry Clin Neurosci 263:159–165CrossRefPubMedGoogle Scholar
  26. 26.
    Grassi-Oliveira R, Brieztke E, Teixeira A, Pezzi JC, Zanini M et al (2012) Peripheral chemokine levels in women with recurrent major depression with suicidal ideation. Rev Bras Psiquiatr 34:71–75CrossRefPubMedGoogle Scholar
  27. 27.
    Gosselin RD, Dansereau MA, Pohl M, Kitabgi P, Beaudet N et al (2008) Chemokine network in the nervous system: a new target for pain relief. Curr Med Chem 15:2866–2875CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  • Halina Duarte
    • 1
  • Antonio L. Teixeira
    • 1
    • 2
  • Natália P. Rocha
    • 2
  • Renan B. Domingues
    • 1
    • 3
    • 4
    Email author
  1. 1.Neurosciences Postgraduation ProgramFederal University of Minas Gerais (UFMG)Belo HorizonteBrazil
  2. 2.Interdisciplinar Laboratory of Medical Investigation, School of MedicineFederal University of Minas Gerais (UFMG)Belo HorizonteBrazil
  3. 3.CHRULilleFrance
  4. 4.CAPES FoudationMinistry of EducationBrasiliaBrazil

Personalised recommendations